Literature DB >> 10428912

Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus.

J R Aeschlimann1, E Hershberger, M J Rybak.   

Abstract

Methicillin-resistant Staphylococcus aureus strains with decreased vancomycin susceptibility have been isolated from patients in the United States and Japan. The impact of decreased vancomycin susceptibility on the drug's pharmacodynamic parameters has not been addressed. We studied the activity of vancomycin against three clinical strains of vancomycin intermediate-susceptible Staphylococcus aureus (VISA) under high- and low-inoculum conditions, with stationary- and logarithmic-growth-phase kill curves, and in postantibiotic effect (PAE) experiments. We also investigated the stability of the decreased vancomycin susceptibility by using population susceptibility profiles. The respective vancomycin microdilution MICs and MBCs for VISA strains HIP5836, 14379, and Mu50 were 8 and 8, 8 and 8, and 8 and 16 microg/ml. HIP5836 had the most homogeneous elevation of vancomycin MICs, because the MIC for nearly all bacteria in the inoculum was 8 microg/ml. The population MICs (defined as the lowest vancomycin concentration inhibiting 99. 9% of growth) for the first serial passages of HIP5836, Mu50, and 14379 were 8, 4, and 2 microg/ml, respectively. After 10 passages, they decreased to 4, 2, and 1 microg/ml, respectively. The Mu50 population MIC increased to 12 microg/ml after five serial passages on vancomycin agar. In the low- and high-inoculum kill curves, time to 99.9% killing was significantly (P < 0.05) longer for both Mu50 and HIP5836 than that for 14379 and a control strain. However, colony counts at 24 h were similar to those of the vancomycin-sensitive strain for all VISA strains. The PAE (at 4x MIC) ranged from 1.3 h for 14379 to 2.0 h for HIP5836 and was similar to or greater than the PAE against the vancomycin-sensitive strain. In conclusion, we found that the decreased vancomycin susceptibility increased during persistent exposures to the drug and decreased upon removal of the selective pressure. The decreased vancomycin susceptibility decreased the rate of vancomycin killing, but did not affect the extent of killing or the PAE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428912      PMCID: PMC89390     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-08-22       Impact factor: 17.586

2.  Staphylococcus aureus and vancomycin: the sequel.

Authors:  A W Karchmer
Journal:  Ann Intern Med       Date:  1991-11-01       Impact factor: 25.391

3.  QUANTITATIVE ACTION OF PENICILLIN INHIBITOR FROM PENICILLIN-RESISTANT STRAINS OF STAPHYLOCOCCI.

Authors:  W W Spink; V Ferris
Journal:  Science       Date:  1945-08-31       Impact factor: 47.728

4.  In-vitro selection of resistance of Staphylococcus aureus to teicoplanin and vancomycin.

Authors:  C Watanakunakorn
Journal:  J Antimicrob Chemother       Date:  1990-01       Impact factor: 5.790

5.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

6.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

Review 7.  Resistance to glycopeptides in enterococci.

Authors:  R Leclercq; P Courvalin
Journal:  Clin Infect Dis       Date:  1997-04       Impact factor: 9.079

8.  Reduced susceptibility of Staphylococcus aureus to vancomycin--Japan, 1996.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-07-11       Impact factor: 17.586

9.  Teicoplanin selects for Staphylococcus aureus that is resistant to vancomycin.

Authors:  D M Shlaes; J H Shlaes
Journal:  Clin Infect Dis       Date:  1995-04       Impact factor: 9.079

10.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

View more
  23 in total

1.  Influence of reduced susceptibility to glycopeptides on activities of vancomycin and teicoplanin against Staphylococcus aureus in experimental endocarditis.

Authors:  Juliette Pavie; Agnès Lefort; Marie-Cécile Ploy; Laurent Massias; Françoise Chau; Louis Garry; François Denis; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

2.  The msaABCR operon regulates resistance in vancomycin-intermediate Staphylococcus aureus strains.

Authors:  Dhritiman Samanta; Mohamed O Elasri
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

3.  Activities of trovafloxacin and ampicillin-sulbactam alone or in combination versus three strains of vancomycin- intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.

Authors:  J R Aeschlimann; E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

4.  Underestimation of vancomycin and teicoplanin MICs by broth microdilution leads to underdetection of glycopeptide-intermediate isolates of Staphylococcus aureus.

Authors:  Pierre Vaudaux; Elzbieta Huggler; Louis Bernard; Tristan Ferry; Adriana Renzoni; Daniel P Lew
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

5.  Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.

Authors:  Wessam Abdelhady; Arnold S Bayer; Kati Seidl; Cynthia C Nast; Megan R Kiedrowski; Alexander R Horswill; Michael R Yeaman; Yan Q Xiong
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

6.  Low frequencies of resistance among Staphylococcus and Enterococcus species to the bactericidal DNA polymerase inhibitor N(3)-hydroxybutyl 6-(3'-ethyl-4'-methylanilino) uracil.

Authors:  Michelle M Butler; Donna J Skow; Ryan O Stephenson; Patrick T Lyden; William A LaMarr; Kimberly A Foster
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

7.  Daptomycin dose-effect relationship against resistant gram-positive organisms.

Authors:  Raymond Cha; Richard G Grucz; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

8.  Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

Authors:  L Cui; H Murakami; K Kuwahara-Arai; H Hanaki; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

9.  Antibacterial activity and mechanism of action of a novel anilinouracil-fluoroquinolone hybrid compound.

Authors:  Michelle M Butler; William A Lamarr; Kimberly A Foster; Marjorie H Barnes; Donna J Skow; Patrick T Lyden; Lauren M Kustigian; Chengxin Zhi; Neal C Brown; George E Wright; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2006-10-30       Impact factor: 5.191

10.  Clinical outcome with oral linezolid and rifampin following recurrent methicillin-resistant Staphylococcus aureus bacteremia despite prolonged vancomycin treatment.

Authors:  Jon-David Schwalm; Philippe El-Helou; Christine H Lee
Journal:  Can J Infect Dis       Date:  2004-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.